Single-cell repertoire tracing identifies rituximab-resistant B cells during myasthenia gravis relapses

Abstract excerpt

Rituximab, a B cell-depleting therapy, is indicated for treating a growing number of autoantibody-mediated autoimmune disorders. However, relapses can occur after treatment, and autoantibody-producing B cell subsets may be found during relapses. It is not understood whether these autoantibody-producing B cell subsets emerge from the failed depletion of preexisting B cells or are generated de novo. To further...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to CAR-T cell therapy research
• Share to Myasthenia Gravis and Thymoma
• Share to T-cell and B-cell Immunology